Switching from IV to SC vedolizumab in IBD: real-world effectiveness and safety over 48 weeks

Subcutaneous (SC) vedolizumab offers practical advantages over intravenous (IV) administration, but real-world data on switching established patients from IV to SC maintenance therapy remain limited, particularly beyond 12 months. This single-centre, retrospective cohort study evaluated 24 adults with inflammatory bowel disease (IBD) who transitioned from IV to SC vedolizumab maintenance therapy between August 2020 and October 2023. Clinical disease activity indices (SCCAI, HBI), biochemical markers (C-reactive protein, faecal calprotectin) and treatment persistence were assessed at weeks 12, 24 and 48. The cohort comprised 10 patients with Crohn’s disease, 12 with ulcerative colitis and 2 with indeterminate IBD. Treatment persistence was 100% at week 12, 92% at week 24 and 71% at week 48; seven patients (29.2%) discontinued, most often for loss of response ( n = 4). Among continuers, clinical and biochemical disease activity remained stable, and median faecal calprotectin was unchanged across timepoints. No serious adverse events or systemic hypersensitivity reactions were documented; one patient had an injection-site reaction prompting return to IV therapy. In this small, single-centre retrospective cohort, switching from IV to SC vedolizumab was associated with acceptable persistence and stable disease control in appropriately selected patients, particularly those in remission at the time of switch.

Authors

Institutions

Publication Details

Journal
npj Autoimmunity
Published
2026-11-17
DOI
https://doi.org/10.1038/s44483-026-00008-z
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Switching from IV to SC vedolizumab in IBD: real-world effectiveness and safety over 48 weeks

Faris Gondal, Andrew Chen, Omar Salehi, Jonathan Philip Segal et al.
2 links
npj Autoimmunity
Inflammatory Bowel Disease
article

Switching from IV to SC vedolizumab in IBD: real-world effectiveness and safety over 48 weeks

Faris Gondal, Andrew Chen, Omar Salehi, Jonathan Philip Segal, Stephanie Dimovski, Clarissa A. Rentsch, Weilun Gao, Finlay Macrae
article en

Abstract

Subcutaneous (SC) vedolizumab offers practical advantages over intravenous (IV) administration, but real-world data on switching established patients from IV to SC maintenance therapy remain limited, particularly beyond 12 months. This single-centre, retrospective cohort study evaluated 24 adults with inflammatory bowel disease (IBD) who transitioned from IV to SC vedolizumab maintenance therapy between August 2020 and October 2023. Clinical disease activity indices (SCCAI, HBI), biochemical markers (C-reactive protein, faecal calprotectin) and treatment persistence were assessed at weeks 12, 24 and 48. The cohort comprised 10 patients with Crohn’s disease, 12 with ulcerative colitis and 2 with indeterminate IBD. Treatment persistence was 100% at week 12, 92% at week 24 and 71% at week 48; seven patients (29.2%) discontinued, most often for loss of response ( n = 4). Among continuers, clinical and biochemical disease activity remained stable, and median faecal calprotectin was unchanged across timepoints. No serious adverse events or systemic hypersensitivity reactions were documented; one patient had an injection-site reaction prompting return to IV therapy. In this small, single-centre retrospective cohort, switching from IV to SC vedolizumab was associated with acceptable persistence and stable disease control in appropriately selected patients, particularly those in remission at the time of switch.

npj AutoimmunityVol. 1(1)
The Royal Melbourne Hospital (AU), Austin Hospital (AU)
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon